


{"id":51007,"date":"2024-03-10T18:31:51","date_gmt":"2024-03-10T16:31:51","guid":{"rendered":"https:\/\/www.fyb.de\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/"},"modified":"2024-03-10T18:31:51","modified_gmt":"2024-03-10T16:31:51","slug":"arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/","title":{"rendered":"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in&nbsp;Italy"},"content":{"rendered":"<p>D\u00fcsseldorf\/Munich \u2014 Karo Health\u00adcare is expan\u00adding its presence in Italy with this acqui\u00adsi\u00adtion. The acqui\u00adsi\u00adtion also streng\u00adthens Karo\u2019s stra\u00adte\u00adgic focus on premium brands in areas asso\u00adcia\u00adted with discom\u00adfort and shame. Proc\u00adto\u00adse\u00addyl\u00ae is a leading brand in Italy for the treat\u00adment of hemor\u00adrhoids. The acqui\u00adsi\u00adtion expands Karo\u2019s posi\u00adtion in one of its core compe\u00adten\u00adcies, diges\u00adtive health, which includes global brands such as Proct\u00ae and Hemoproct\u00ae.<\/p>\n<p>ARQIS advi\u00adsed Karo Health\u00adcare on the acqui\u00adsi\u00adtion of Proc\u00adto\u00adse\u00addyl\u00ae from Bayer. The tran\u00adsac\u00adtion gives Karo the exclu\u00adsive distri\u00adbu\u00adtion rights to the OTC product in&nbsp;Italy.<\/p>\n<p>\u201cThis acqui\u00adsi\u00adtion adds a trus\u00adted brand that covers an often negle\u00adc\u00adted cate\u00adgory with untap\u00adped poten\u00adtial. We are exci\u00adted about the oppor\u00adtu\u00adnity to improve access to relia\u00adble treat\u00adments for Italian consu\u00admers and further expand our Italian busi\u00adness,\u201d said Matt Roberts, CCO of Karo Healthcare.<\/p>\n<p>The acqui\u00adsi\u00adtion was carried out as an asset deal, without person\u00adnel and produc\u00adtion faci\u00adli\u00adties, which redu\u00adces the commer\u00adcial risk and ensu\u00adres seam\u00adless inte\u00adgra\u00adtion. Karo will use its exis\u00adting infra\u00adstruc\u00adture and rely on estab\u00adlished part\u00adners in&nbsp;Italy.<\/p>\n<p>The ARQIS team around  <strong>J\u00f6rn-Chr. Schulze (Photo \u00a9 arqis)<\/strong>  acted for the first time for Karo Health\u00adcare, a Swedish EQT invest\u00adment company. The team\u2019s healthcare\/life science and private equity focus were decisive for the mandate.<\/p>\n<p><strong>Advi\u00adsor Karo Health\u00adcare: ARQIS (D\u00fcsseldorf\/Munich)<\/strong><\/p>\n<p>Dr. J\u00f6rn-Chris\u00adtian Schulze (Lead Part\u00adner), Dr. Maxi\u00admi\u00adlian Back\u00adhaus, Malte Grie\u00adpen\u00adburg (all Tran\u00adsac\u00adtions), Part\u00adners: Dr. Fried\u00adrich Gebert (Regu\u00adla\u00adtory), Marcus Noth\u00adhel\u00adfer (IP), Mana\u00adging Asso\u00adcia\u00adtes: Daniel Schle\u00admann (Data Law), Rolf Tichy (IP), Asso\u00adciate: Dr. Bern\u00adhard Gr\u00f6he (Regu\u00adla\u00adtory), Trade\u00admark Profes\u00adsio\u00adnal: Caro\u00adlin von Fritsch<\/p>\n<p><strong>Fran\u00adzosi \u2014 Dal Negro \u2014 Setti<\/strong> (Milan) Stefano Giberti, Fran\u00adcesco Setti (both Italian regu\u00adla\u00adtory&nbsp;law)<\/p>\n<p><strong>About ARQIS<\/strong><\/p>\n<p>ARQIS is an inde\u00adpen\u00addent busi\u00adness law firm opera\u00adting inter\u00adna\u00adtio\u00adnally. Around 80 lawy\u00aders and legal specia\u00adlists advise dome\u00adstic and foreign compa\u00adnies at the highest level on German, Euro\u00adpean and Japa\u00adnese commer\u00adcial law. With the focus groups Tran\u00adsac\u00adtions, HR.Law, Japan, Data.Law, Risk and Regu\u00adla\u00adtory, the firm is geared towards provi\u00adding compre\u00adhen\u00adsive advice to its clients. The law firm was foun\u00added in 2006 and has offices in D\u00fcssel\u00addorf, Munich and Tokyo as well as a talent hub in Berlin. For more infor\u00adma\u00adtion, visit www.arqis.com.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>D\u00fcsseldorf\/Munich \u2014 Karo Health\u00adcare is expan\u00adding its presence in Italy with this acqui\u00adsi\u00adtion. The acqui\u00adsi\u00adtion also streng\u00adthens Karo\u2019s stra\u00adte\u00adgic focus on premium brands in areas asso\u00adcia\u00adted with discom\u00adfort and shame. Proc\u00adto\u00adse\u00addyl\u00ae is a leading brand in Italy for the treat\u00adment of hemor\u00adrhoids. The acqui\u00adsi\u00adtion expands Karo\u2019s posi\u00adtion in one of its core compe\u00adten\u00adcies, diges\u00adtive health,&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":51009,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1368,1372,2635],"tags":[],"class_list":["post-51007","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-consultants-auditors","category-consultant","category-corporate-finance-mergers-acquisitions-en-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in Italy - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in Italy - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"D\u00fcsseldorf\/Munich \u2014 Karo Health\u00adcare is expan\u00adding its presence in Italy with this acqui\u00adsi\u00adtion. The acqui\u00adsi\u00adtion also streng\u00adthens Karo\u2019s stra\u00adte\u00adgic focus on premium brands in areas asso\u00adcia\u00adted with discom\u00adfort and shame. Proc\u00adto\u00adse\u00addyl\u00ae is a leading brand in Italy for the treat\u00adment of hemor\u00adrhoids. The acqui\u00adsi\u00adtion expands Karo\u2019s posi\u00adtion in one of its core compe\u00adten\u00adcies, diges\u00adtive health, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-10T16:31:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-e1710088230943.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in&nbsp;Italy\",\"datePublished\":\"2024-03-10T16:31:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/\"},\"wordCount\":369,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers, tax consultants, auditors\",\"Consultant\",\"corporate-finance-mergers-acquisitions-en\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/\",\"url\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/\",\"name\":\"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in Italy - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg\",\"datePublished\":\"2024-03-10T16:31:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg\",\"width\":764,\"height\":543},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in&nbsp;Italy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in Italy - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/","og_locale":"en_US","og_type":"article","og_title":"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in Italy - FYB Financial Yearbook","og_description":"D\u00fcsseldorf\/Munich \u2014 Karo Health\u00adcare is expan\u00adding its presence in Italy with this acqui\u00adsi\u00adtion. The acqui\u00adsi\u00adtion also streng\u00adthens Karo\u2019s stra\u00adte\u00adgic focus on premium brands in areas asso\u00adcia\u00adted with discom\u00adfort and shame. Proc\u00adto\u00adse\u00addyl\u00ae is a leading brand in Italy for the treat\u00adment of hemor\u00adrhoids. The acqui\u00adsi\u00adtion expands Karo\u2019s posi\u00adtion in one of its core compe\u00adten\u00adcies, diges\u00adtive health, [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2024-03-10T16:31:51+00:00","og_image":[{"width":800,"height":1200,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-e1710088230943.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in&nbsp;Italy","datePublished":"2024-03-10T16:31:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/"},"wordCount":369,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg","articleSection":["General","Featured","News","Lawyers, tax consultants, auditors","Consultant","corporate-finance-mergers-acquisitions-en"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/","url":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/","name":"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in Italy - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg","datePublished":"2024-03-10T16:31:51+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/03\/joern-chr-schulze-arqis-1.jpg","width":764,"height":543},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/arqis-advises-karo-healthcare-on-proctosedyl-acquisition-from-bayer-in-italy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"ARQIS advises Karo Healthcare on Proctosedyl\u00ae acquisition from Bayer in&nbsp;Italy"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/51007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=51007"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/51007\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/51009"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=51007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=51007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=51007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}